Explanation
Patientsshouldbemonitoredfordevelopmemtofuivertoxicity
Bosentanisacompetitive antaaonistat bothendothetin-A ETA) and endothetin-B ETB)receptors.Ieadinqto
falsinbothpuumonarv andsvstemicvascularresistances without an increase inheart rate.tisoneofthefew
treatmentsthatshowefficacvin oatientswthouumonarv arteriauhvpertension.Common unwantedeffects
includefuushina.hypotension.dyspepsiaandfatiaue.Themostserious adverse effectisdose-dependent
hepatotoxicity,and
sthereforecontraindicatec
patientswith moderatetosevereuiver disease.
Hepatotoxicity normally occurswithinthefirst
4monthsoftreatment.andpatientsshould haveliver
functiontestsLFTs) monitored
@1MINENDOCRINE
